Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Acquired by Vanguard Group Inc.

Vanguard Group Inc. raised its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 1.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,878,451 shares of the company's stock after acquiring an additional 28,707 shares during the quarter. Vanguard Group Inc. owned approximately 10.01% of Krystal Biotech worth $450,938,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in KRYS. LPL Financial LLC increased its stake in Krystal Biotech by 156.8% in the fourth quarter. LPL Financial LLC now owns 2,946 shares of the company's stock valued at $462,000 after purchasing an additional 1,799 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in Krystal Biotech during the 4th quarter worth $339,000. KLP Kapitalforvaltning AS purchased a new stake in Krystal Biotech in the fourth quarter valued at $674,000. Summit Global Investments acquired a new position in Krystal Biotech in the fourth quarter valued at $541,000. Finally, Teacher Retirement System of Texas grew its holdings in shares of Krystal Biotech by 27.3% during the fourth quarter. Teacher Retirement System of Texas now owns 6,383 shares of the company's stock worth $1,000,000 after purchasing an additional 1,369 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company's stock.

Krystal Biotech Stock Down 3.8 %

NASDAQ KRYS traded down $6.83 during trading hours on Friday, hitting $171.30. 444,673 shares of the stock were exchanged, compared to its average volume of 292,083. Krystal Biotech, Inc. has a 12-month low of $141.72 and a 12-month high of $219.34. The stock has a 50-day moving average of $173.27 and a 200 day moving average of $173.00. The company has a market cap of $4.93 billion, a price-to-earnings ratio of 57.29 and a beta of 0.75.

Remove Ads

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm had revenue of $91.10 million during the quarter, compared to analysts' expectations of $91.35 million. During the same quarter in the prior year, the business posted $0.30 earnings per share. Krystal Biotech's revenue was up 116.4% compared to the same quarter last year. On average, equities research analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on KRYS. HC Wainwright reissued a "buy" rating and issued a $221.00 target price on shares of Krystal Biotech in a research report on Friday, February 28th. Jefferies Financial Group started coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 target price on the stock. Citigroup increased their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research note on Thursday, February 20th. Chardan Capital lifted their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research note on Thursday, February 20th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $220.00.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the transaction, the insider now owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. The trade was a 1.68 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by corporate insiders.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).